advertisement

Topcon

Kuehn MH 11

Showing records 1 to 11 | Display all abstracts from Kuehn MH

98756 Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
McDowell CM
Investigative Ophthalmology and Visual Science 2022; 63: 12
98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Zeng H
Biomolecules 2022; 12:
98756 Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
Kizhatil K
Investigative Ophthalmology and Visual Science 2022; 63: 12
98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Dumitrescu AV; Wadkins D
Biomolecules 2022; 12:
98756 Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
Elliott MH
Investigative Ophthalmology and Visual Science 2022; 63: 12
98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Elwood BW
Biomolecules 2022; 12:
98756 Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
Overby DR
Investigative Ophthalmology and Visual Science 2022; 63: 12
98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Gramlich OW
Biomolecules 2022; 12:
98756 Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
van Batenburg-Sherwood J; van Batenburg-Sherwood J
Investigative Ophthalmology and Visual Science 2022; 63: 12
98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Kuehn MH
Biomolecules 2022; 12:
98756 Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
Millar JC; Kuehn MH; Zode G; Acott TS; Anderson MG; Bhattacharya SK; Bertrand JA; Borras T; Bovenkamp DE; Bovenkamp DE; Cheng L; Danias J; De Ieso ML; Du Y; Faralli JA; Fuchshofer R; Ganapathy PS; Gong H; Herberg S; Hernandez H; Humphries P; John SWM; Kaufman PL; Keller KE; Kelley MJ; Kelly RA; Krizaj D; Kumar A; Leonard BC; Lieberman RL; Liton P; Liu Y; Liu KC; Lopez NN; Mao W; Mavlyutov T; McDonnell F; McLellan GJ; Mzyk P; Mzyk P; Nartey A; Nartey A; Pasquale LR; Patel GC; Pattabiraman PP; Peters DM; Raghunathan V; Rao PV; Rayana N; Raychaudhuri U; Reina-Torres E; Ren R; Rhee D; Chowdhury UR; Samples JR; Samples EG; Sharif N; Schuman JS; Sheffield VC; Stevenson CH; Soundararajan A; Subramanian P; Subramanian P; Sugali CK; Sun Y; Toris CB; Torrejon KY; Vahabikashi A; Vranka JA; Wang T; Willoughby CE; Xin C; Yun H; Zhang HF; Fautsch MP; Tamm ER; Clark AF; Ethier CR; Stamer WD
Investigative Ophthalmology and Visual Science 2022; 63: 12

Issue 22-4

Change Issue


advertisement

Oculus